全文获取类型
收费全文 | 193820篇 |
免费 | 3983篇 |
国内免费 | 434篇 |
学科分类
医药卫生 | 198237篇 |
出版年
2018年 | 3485篇 |
2017年 | 3842篇 |
2016年 | 3131篇 |
2015年 | 4827篇 |
2014年 | 4237篇 |
2013年 | 3328篇 |
2012年 | 9750篇 |
2011年 | 4595篇 |
2010年 | 2159篇 |
2009年 | 3812篇 |
2008年 | 1978篇 |
2007年 | 2746篇 |
2006年 | 2998篇 |
2005年 | 11116篇 |
2004年 | 12573篇 |
2003年 | 8167篇 |
2002年 | 3401篇 |
2001年 | 4384篇 |
2000年 | 1714篇 |
1999年 | 5864篇 |
1998年 | 523篇 |
1995年 | 379篇 |
1992年 | 6880篇 |
1991年 | 7113篇 |
1990年 | 7359篇 |
1989年 | 6942篇 |
1988年 | 6475篇 |
1987年 | 6246篇 |
1986年 | 5953篇 |
1985年 | 5248篇 |
1984年 | 3591篇 |
1983年 | 2911篇 |
1982年 | 999篇 |
1981年 | 766篇 |
1980年 | 835篇 |
1979年 | 3827篇 |
1978年 | 2361篇 |
1977年 | 1782篇 |
1976年 | 1559篇 |
1975年 | 2475篇 |
1974年 | 3106篇 |
1973年 | 2738篇 |
1972年 | 2756篇 |
1971年 | 2741篇 |
1970年 | 2555篇 |
1969年 | 2464篇 |
1968年 | 2237篇 |
1967年 | 2163篇 |
1966年 | 1898篇 |
1965年 | 1131篇 |
排序方式: 共有10000条查询结果,搜索用时 16 毫秒
1.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
3.
4.
5.
6.
肿瘤内微生物群(组)已被证实广泛存在于各类肿瘤内,对肿瘤微环境的形成、调控肿瘤生长均发挥着重要作用,并直接影响药物干预肿瘤的疗效。随着新一代基因测序技术的广泛应用,针对肿瘤内微生物功能和分类的研究日益增温。诸多研究表明不同肿瘤内微生物种属分布不同,且不同种微生物所发挥的促/抑瘤机制不同。针对肿瘤内微生物的编辑技术亦取得了许多成果,有望成为检测与治疗肿瘤的新手段。本文旨在对近年来肿瘤内微生物群(组)相关研究进展加以综述,并展望其应用前景。 相似文献
7.
8.
9.
J. Funk N. Biber M. Schneider E. Hauser S. Enzenmüller C. F?rtsch H. Barth H. Schmidt 《Infection and immunity》2015,83(6):2338-2349
In this study, the cytotoxicity of the recently described subtilase variant SubAB2-2 of Shiga toxin-producing Escherichia coli was determined and compared to the plasmid-encoded SubAB1 and the chromosome-encoded SubAB2-1 variant. The genes for the respective enzymatic active (A) subunits and binding (B) subunits of the subtilase toxins were amplified and cloned. The recombinant toxin subunits were expressed and purified. Their cytotoxicity on Vero cells was measured for the single A and B subunits, as well as for mixtures of both, to analyze whether hybrids with toxic activity can be identified. The results demonstrated that all three SubAB variants are toxic for Vero cells. However, the values for the 50% cytotoxic dose (CD50) differ for the individual variants. Highest cytotoxicity was shown for SubAB1. Moreover, hybrids of subunits from different subtilase toxins can be obtained which cause substantial cytotoxicity to Vero cells after mixing the A and B subunits prior to application to the cells, which is characteristic for binary toxins. Furthermore, higher concentrations of the enzymatic subunit SubA1 exhibited cytotoxic effects in the absence of the respective B1 subunit. A more detailed investigation in the human HeLa cell line revealed that SubA1 alone induced apoptosis, while the B1 subunit alone did not induce cell death. 相似文献
10.
After 4 years of early benefit assessment (EBA) in Germany, it is becoming evident that the Federal Joint Committee (FJC) frequently considers well-established clinical endpoints as not being relevant to patients. Focusing on assessments of oncology medicines, we analysed the FJC’s view on primary endpoints and compared it with the approach used by regulatory authorities. Mortality data were accepted by both stakeholders. Whereas regulatory authorities accepted primary morbidity endpoints such as progression-free survival and response rates, the FJC mostly excluded these from its assessments. Health-related quality of life (HRQoL) data have been poorly reflected in the approval process; for EBAs, those data have rarely impacted on benefit ratings. We argue that agreement between regulatory authorities and the FJC is required regarding primary study endpoints that are relevant to patients, and that clarification of acceptable endpoints by the FJC, especially in the morbidity domain, has to be provided. Moreover, in order to fully acknowledge the benefit of a new medicinal product, mortality, morbidity and HRQoL should be weighted differentially, according to the condition. 相似文献